Correlation between the pulmonary immune prognostic index and prognosis of advanced non-small cell lung cancer patients treated with sintilimab
- VernacularTitle:肺免疫预后指数与信迪利单抗治疗晚期非小细胞肺癌患者预后的相关性
- Author:
Xuzhi WEN
1
;
Chunni XU
;
Guobiao HONG
;
Xuexin LUO
;
Wenwei CHEN
Author Information
- Keywords: non-small cell lung cancer; sintilimab; pulmonary immune prognostic index; overall survival; progression-free survival
- From: Journal of Clinical Medicine in Practice 2025;29(3):17-21,29
- CountryChina
- Language:Chinese
- Abstract: Objective To analyze the correlation between the pulmonary immune prognostic index(LIPI)and the prognosis of patients with advanced non-small cell lung cancer(NSCLC)treated with sintilimab.Methods A total of 145 patients with advanced NSCLC were selected as study subjects.All patients received treatment with sintilimab,and their clinical baseline data were recorded.Accord-ing to the LIPI score,patients were divided into low-risk,intermediate-risk,and high-risk groups.The correlation between LIPI and the prognosis of advanced NSCLC patients was analyzed.Factors in-fluencing progression-free survival(PFS)and overall survival(OS)were identified.Results Univa-riate analysis showed that patient age,smoking status,pathological type,clinical stage and LIPI were factors affecting PFS(P＜0.05);age,pathological type,clinical stage and LIPI were factors affecting OS(P＜0.05).Multivariate Logistic regression analysis revealed that age of 60 to 70 years,age＞70 years,adenocarcinoma,stage Ⅳ and high-risk LIPI were independent prognostic factors of PFS(P＜0.05);age＞70 years,poor stage Ⅳ,adenocarcinoma and high-risk LIPI were independent prognos-tic factors of OS(P＜0.05).LIPI influenced patient's prognosis,with low-risk patients showing better outcomes and longer median PFS and OS.Conclusion LIPI is correlated with the prognosis of advanced NSCLC patients treated with sintilimab.Patients with a low-risk LIPI assessment benefit more from sintilimab treatment.
